

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13751-0055US1	Application No. 10/540,959
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Paul D. Rennert		
		Filing Date April 4, 2006	Group Art Unit 1644	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
/MH/	1	EP1062949	12/27/2000	EP			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>							
Examiner Initial	Desig. ID	Document					
/MH/	2	Brams, P. et al., "A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation," International Immunopharmacology Elsevier, Amsterdam, NL (2001), 1(2):277-294.					
/MH/	3	Saxena, M. et al., "Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTO)," The Journal of Biological Chemistry (1999), 274(17):11693-11700.					
/MH/	4	Umetsu Dale, T. et al., "Asthma: an epidemic of dysregulated immunity," Nature Immunology (2002, 3(8):715-720.					
/MH/	5	Xia T., et al., "Cimetidine inhibits production of interferon gamma and tumor necrosis factor alpha by splenocytes in aplastic anemic mice," Acta Pharmacologica Sinica (2001), 22(3):239-242.					

Examiner Signature /Maher Haddad/	Date Considered 03/09/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	